Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryMay052021	Fate Therapeutics Reports First Quarter 2021 Financial Results and Highlights Operational Progress IND Application Allowed by FDA for FT538 in Solid Tumors; Clinical Trial to Commence in 2021 Phase 1 Data from FT516 and FT538 Programs in Relapsed / Refractory Acute Myeloid Leukemia to be Featured at Investor Event on May 13 New Data from FT516 Phase 1 Study in Relapsed / Refractory Lymphoma to Read All »	View HTML
Toggle SummaryApr292021	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2021 Financial Results SAN DIEGO , April 29, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced today that the Company will host a Read All »	View HTML
Toggle SummaryApr272021	Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting Two Oral Presentations to Cover iPSC-derived Cell-based Cancer Immunotherapy Pipeline Company to Host Investor Event on May 13 to Highlight Interim Phase 1 Clinical Data from the Company’s FT516 and FT538 Programs for Relapsed / Refractory AML SAN DIEGO , April 27, 2021 (GLOBE NEWSWIRE) -- Fate Read All »	View HTML
Toggle SummaryMar252021	Fate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service SAN DIEGO , March 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that Daniel D. Read All »	View HTML
Toggle SummaryMar082021	Fate Therapeutics to Present at Upcoming Investor Conferences SAN DIEGO , March 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced today that the Company will present at Read All »	View HTML
Toggle SummaryFeb242021	Fate Therapeutics Reports Fourth Quarter 2020 Financial Results and Highlights Operational Progress Positive Interim Data Reported from FT516 Phase 1 Study in Relapsed / Refractory BCL; Objective Responses, including Two Complete Responses, Achieved in 3 of 4 Patients in Dose Cohorts 2 and 3 Clinical Activity of FT596 as Monotherapy Demonstrated in Refractory DLBCL; Partial Response Achieved, Read All »	View HTML
Toggle SummaryFeb222021	Fate Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference SAN DIEGO , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced today that the Company will present at Read All »	View HTML
Toggle SummaryFeb192021	Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2020 Financial Results SAN DIEGO , Feb. 19, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced today that the Company will host a Read All »	View HTML
Toggle SummaryJan082021	Fate Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants, and Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN DIEGO , Jan. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing Read All »	View HTML
Toggle SummaryJan062021	Fate Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants SAN DIEGO , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the pricing Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.